DexCom, Inc. · DXCM · Next earnings

DexCom, Inc. reports Thursday, Oct 29, 2026

DXCM reports after market close with consensus EPS at $0.66 and revenue at $1.33B. Last quarter: Dexcom Beats Q1 Estimates as G7 15-Day Sensor Drives Record Patient Starts

Reports After market close39 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.66 Calendar consensus
Consensus revenue $1.33B Calendar consensus
Report date Oct 29, 2026 Thursday, date estimated
Session After market close 39 days away

Where DXCM left off: FY2026 Q1

Full report

Dexcom Beats Q1 Estimates as G7 15-Day Sensor Drives Record Patient Starts

EPS surprise +20.3% Reported $0.56 vs $0.47
Revenue surprise +1.5% Reported $1.19B vs $1.17B
Stock move +3.0% Event window
Subsequent drift +22.0% Up to 20 sessions

Full-year FY2026 revenue guidance reaffirmed at $5.16-$5.20B, narrowing the prior $5.16-$5.25B range at the upper end. Non-GAAP operating and EBITDA margin targets were raised. A new 50-100 bps gross margin headwind from oil and resin inflation was disclosed. Guidance sentiment: maintained.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • 50-100 bps gross margin headwind from oil and resin price inflation
  • Uncertainty around timing and scope of CMS coverage for type-2 non-insulin patients
  • Competitive pressure in a potentially slowing U.S. CGM market
  • Foreign exchange impact on reported international results
  • Execution risk on international Stello launch and new CGM system introduction

Questions analysts left open

  • Whether the U.S. market can sustain double-digit growth without a record new-patient start
  • Margin impact of the 15-day rollout versus inflationary headwinds
  • Timing and likelihood of CMS coverage for type-2 non-insulin patients
  • Performance and timing of international growth and tender wins
  • Results and publication timeline of the type-2 non-insulin RCT

Ask FN2 about DXCM next report

Transcript, numbers and history already loaded
What should I watch for in DXCM's next earnings report?How did DXCM guide last quarter, and is consensus above or below that?Give me the bull and bear case going into DXCM earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the DXCM recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent DXCM quarters

All DXCM earnings
+3.0%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.